Literature DB >> 29335523

miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1.

Shengni Hua1, Ling Lei1, Ling Deng1, Xie Weng2, Chengdong Liu1, Xiaolong Qi3, Shuang Wang4, Dongyan Zhang1, Xuejing Zou2, Chuanhui Cao1, Li Liu5, Dehua Wu6.   

Abstract

Cancer cells have metabolic features that allow them to preferentially metabolize glucose through aerobic glycolysis, providing them with a progression advantage. However, microRNA (miRNA) regulation of aerobic glycolysis in cancer cells has not been extensively investigated. We addressed this in the present study by examining the regulation of miR-139-5p on aerobic glycolysis of hepatocellular carcinoma (HCC) using clinical specimens, HCC cells, and a mouse xenograft model. We found that overexpressing miR-139-5p restrained aerobic glycolysis, suppressing proliferation, migration, and invasion in HCC cells. miR-139-5p regulated hexokinase 1 (HK1) and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) expression by directly targeting the transcription factor ETS1, which bound to the promoters of the HK1 and PFKFB3 genes. miR-139-5p-induced aerobic glycolysis, proliferation, migration, and invasion were reversed by ETS1 overexpression, while ETS1 silencing induced the expression of miR-139-5p via a post-transcriptional regulation mode involving Drosha. miR-139-5p expression was reduced in HCC compared to para-carcinoma tissue, which was confirmed in The Cancer Genome Atlas and GSE54751 HCC cohorts. Notably, the lower expression of mir-139 was correlated with worse prognosis. These outcomes indicate that reciprocal regulatory interactions between miR-139-5p and ETS1 modulate aerobic glycolysis, proliferation, and metastasis in HCC cells, suggesting new targets for HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29335523     DOI: 10.1038/s41388-017-0057-3

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development.

Authors:  Jessica Endig; Laura Elisa Buitrago-Molina; Silke Marhenke; Florian Reisinger; Anna Saborowski; Jutta Schütt; Florian Limbourg; Christian Könecke; Alina Schreder; Alina Michael; Ana Clara Misslitz; Marc Eammonn Healy; Robert Geffers; Thomas Clavel; Dirk Haller; Kristian Unger; Milton Finegold; Achim Weber; Michael P Manns; Thomas Longerich; Mathias Heikenwälder; Arndt Vogel
Journal:  Cancer Cell       Date:  2016-07-28       Impact factor: 31.743

3.  HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells.

Authors:  Wei Bao; Hai-Jing Fu; Qiao-Sheng Xie; Lei Wang; Rui Zhang; Zhang-Yan Guo; Jing Zhao; Yan-Ling Meng; Xin-Ling Ren; Tao Wang; Qing Li; Bo-Quan Jin; Li-Bo Yao; Rui-An Wang; Dai-Ming Fan; Si-Yi Chen; Lin-Tao Jia; An-Gang Yang
Journal:  Gastroenterology       Date:  2011-09-16       Impact factor: 22.682

4.  miRNA-126 Orchestrates an Oncogenic Program in B Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Silvia Nucera; Alice Giustacchini; Francesco Boccalatte; Andrea Calabria; Cristiana Fanciullo; Tiziana Plati; Anna Ranghetti; Jose Garcia-Manteiga; Davide Cittaro; Fabrizio Benedicenti; Eric R Lechman; John E Dick; Maurilio Ponzoni; Fabio Ciceri; Eugenio Montini; Bernhard Gentner; Luigi Naldini
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

5.  MiR-33 contributes to the regulation of cholesterol homeostasis.

Authors:  Katey J Rayner; Yajaira Suárez; Alberto Dávalos; Saj Parathath; Michael L Fitzgerald; Norimasa Tamehiro; Edward A Fisher; Kathryn J Moore; Carlos Fernández-Hernando
Journal:  Science       Date:  2010-05-13       Impact factor: 47.728

Review 6.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

7.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

Review 8.  Understanding the role of ETS-mediated gene regulation in complex biological processes.

Authors:  Victoria J Findlay; Amanda C LaRue; David P Turner; Patricia M Watson; Dennis K Watson
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

9.  Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas.

Authors:  Eri Hiroki; Jun-Ichi Akahira; Fumihiko Suzuki; Satoru Nagase; Kiyoshi Ito; Takashi Suzuki; Hironobu Sasano; Nobuo Yaegashi
Journal:  Cancer Sci       Date:  2009-10-08       Impact factor: 6.716

10.  Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.

Authors:  O Chabre; R Libé; G Assie; O Barreau; J Bertherat; X Bertagna; J-J Feige; N Cherradi
Journal:  Endocr Relat Cancer       Date:  2013-07-05       Impact factor: 5.678

View more
  50 in total

1.  Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Bin Yu; Youming Ding; Xiaofeng Liao; Changhua Wang; Bin Wang; Xiaoyan Chen
Journal:  Dig Dis Sci       Date:  2019-04-04       Impact factor: 3.199

Review 2.  Non-coding RNAs: emerging regulators of glucose metabolism in hepatocellular carcinoma.

Authors:  Yongting Lai; Hairong Huang; Mubalake Abudoureyimu; Xinrong Lin; Chuan Tian; Ting Wang; Xiaoyuan Chu; Rui Wang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  The long non-coding RNA MIAT/miR-139-5p/MMP2 axis regulates cell migration and invasion in non-small-cell lung cancer.

Authors:  Fanye Zeng; Ning Yu; Yanyan Han; Julaiti Ainiwaer
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

4.  miR-139-5p promotes neovascularization in diabetic retinopathy by regulating the phosphatase and tensin homolog.

Authors:  Zhongwei Zhang; Caiping Song; Tao Wang; Lei Sun; Ling Qin; Jianghua Ju
Journal:  Arch Pharm Res       Date:  2021-02-20       Impact factor: 4.946

5.  Up-regulation of SNHG6 activates SERPINH1 expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression.

Authors:  Gang Wu; Xueming Ju; Youyu Wang; Zhixi Li; Xianfeng Gan
Journal:  Cell Cycle       Date:  2019-07-01       Impact factor: 4.534

Review 6.  Glycolysis in the progression of pancreatic cancer.

Authors:  Xinyao Chang; Xingchen Liu; Haoze Wang; Xuan Yang; Yan Gu
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

7.  Candidate lncRNA-miRNA-mRNA network in predicting hepatocarcinogenesis with cirrhosis: an integrated bioinformatics analysis.

Authors:  Rui Zhang; Ying-Yi Jiang; Kun Xiao; Xiao-Quan Huang; Jian Wang; Shi-Yao Chen
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-22       Impact factor: 4.553

8.  MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Authors:  Jianan Chen; Yan Yu; Xiaolong Chen; Yuting He; Qiuyue Hu; Hongqiang Li; Qicai Han; Fang Ren; Juan Li; Chao Li; Jie Bao; Zhigang Ren; Zhenfeng Duan; Guangying Cui; Ranran Sun
Journal:  Cell Prolif       Date:  2018-08-13       Impact factor: 6.831

9.  MiR-139 Modulates Cancer Stem Cell Function of Human Breast Cancer through Targeting CXCR4.

Authors:  Chun-Wen Cheng; Wen-Ling Liao; Po-Ming Chen; Jyh-Cherng Yu; Hui-Ping Shiau; Yi-Hsien Hsieh; Huei-Jane Lee; Yu-Chun Cheng; Pei-Ei Wu; Chen-Yang Shen
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

10.  The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics.

Authors:  Feng Xiao; Jiayu Liu; Yongbo Zheng; Zhen Quan; Wei Sun; Yao Fan; Chunli Luo; Hailiang Li; Xiaohou Wu
Journal:  J Biomater Appl       Date:  2020-12-06       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.